vTv Therapeutics Reports Q2 2025 Financials, Advances Cadisegliatin Trials, and Appoints New CFO

vTv Therapeutics reported a Q2 2025 net loss of $6.0 million, up from $5.2 million in Q2 2024. The company's cash reserves stand at $25.9 million. Notable advancements include the start of patient randomization in the Phase 3 CATT1 trial for cadisegliatin, with topline results expected in H2 2026. Intellectual property for cadisegliatin has been expanded, with patent protection now extending through 2041. New leadership includes Michael Tung as CFO.

vTv Therapeutics (Nasdaq: VTVT) has reported its financial results for the second quarter of 2025, highlighting a net loss of $6.0 million, an increase from $5.2 million in Q2 2024. The company's cash position stands at $25.9 million, down from $36.7 million at year-end 2024, indicating a 29.4% decline. Research and development (R&D) expenses increased to $4.1 million from $3.4 million year-over-year, while general and administrative (G&A) expenses slightly decreased to $3.6 million.

Significant advancements in the company's clinical pipeline include the start of patient randomization in the Phase 3 CATT1 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes (T1D). The trial, which received FDA Breakthrough Therapy designation, aims to evaluate cadisegliatin's efficacy in reducing hypoglycemic events in adults with T1D. Topline results are expected in the second half of 2026. The company has also expanded its intellectual property portfolio for cadisegliatin, with patent protection now extending through 2041. Additionally, Michael Tung has been appointed as the company's new Chief Financial Officer.

The company's financial performance and clinical progress highlight both challenges and opportunities. The increasing cash burn and accelerating net loss indicate the financial strain of advancing the lead program. However, the Phase 3 trial and patent extension position vTv Therapeutics as a leader in the development of innovative diabetes treatments. Investors should closely monitor the company's ability to fund operations through its clinical development timeline without significant dilution.

References:
[1] https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-reports-second-quarter-2025-financial-results-and-khfw3o3me1ka.html
[2] https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-announces-first-study-participant-randomized-in-otqsuitte075.html